WEST

# Freeform Search

**Database:** US Patents Full-Text Database; JPO Abstracts Database; EPO Abstracts Database; Derwent World Patents Index; IBM Technical Disclosure Bulletins

**Term:** patient same l1 same mixture

**Display:** 10 **Documents in Display Format:** CIT **Starting with Number** 1

**Generate:** ○ Hit List ◉ Hit Count ○ Image

Search | Clear | Help | Logout | Interrupt

Main Menu | Show S Numbers | Edit S Numbers | Preferences

## Search History

**Today's Date: 1/17/2001**

| DB Name | Query | Hit Count | Set Name |
|---|---|---|---|
| USPT,JPAB,EPAB,DWPI,TDBD | patient same l1 same mixture | 15 | L2 |
| USPT,JPAB,EPAB,DWPI,TDBD | ozone same oxygen | 11749 | L1 |

WEST

Generate Collection

L2: Entry 8 of 15 File: JPAB Apr 4, 1995

PUB-NO: JP407087965A
DOCUMENT-IDENTIFIER: JP 07087965 A
TITLE: PRODUCTION OF CELL CULTURE WITH ELEVATED CONTENT OF ENDOGENOUS CYTOKINE

PUBN-DATE: April 4, 1995

INVENTOR-INFORMATION:

| NAME | COUNTRY |
|---|---|
| KIEF, HORST | N/A |

ASSIGNEE-INFORMATION:

| NAME | COUNTRY |
|---|---|
| KIEF HORST | N/A |

APPL-NO: JP05352187
APPL-DATE: December 28, 1993

INT-CL (IPC): C12N 5/06; C12P 21/00; A61K 38/00; A61K 38/21

ABSTRACT:

PURPOSE: To produce an endogenous cytokine having great permissibility in a high yield at a low cost.

CONSTITUTION: This method for producing a cell culture comprises culturing the cell culture in a usual fashion and adding a lysate obtained by ozonolysis and proteolysis from blood or a blood fraction and/or urine as a stimulant in a method for producing the cell culture with an increased content of an endogenous cytokine comprising treating a patient's own blood with an ozone-oxygen mixture and fractionating the treated mixture.

WEST

Generate Collection

L2: Entry 7 of 15 File: USPT Oct 1, 1991

DOCUMENT-IDENTIFIER: US 5052382 A
TITLE: Apparatus for the controlled generation and administration of ozone

CLPR:
3. Apparatus according to claim 1 wherein the output means is for treating a patient's blood, said output means comprising a dose discharge syringe means which is driven by a stepper motor for discharging controlled doses of a mixture of oxygen and ozone for the patient's blood, and a purge means for purging the blood treating means with the mixture of ozone and oxygen prior to treating the patient's blood.

WEST

**End of Result Set**

☐ Generate Collection

L2: Entry 15 of 15 File: DWPI Oct 20, 1988

DERWENT-ACC-NO: 1988-300491
DERWENT-WEEK: 198843


TITLE: Injection of anticoagulant into blood - involves capsule attached to flexible hose connected to cannula to withdraw blood from patient

INVENTOR: GRIESEL, H

PATENT-ASSIGNEE:

| ASSIGNEE | CODE |
|---|---|
| GRIESEL H | GRIEI |

PRIORITY-DATA: 1987DE-3710998 (April 1, 1987)

PATENT-FAMILY:

| PUB-NO | PUB-DATE | LANGUAGE | PAGES | MAIN-IPC |
|---|---|---|---|---|
| DE 3710998 A | October 20, 1988 | N/A | 003 | N/A |

APPLICATION-DATA:

| PUB-NO | APPL-DATE | APPL-NO | DESCRIPTOR |
|---|---|---|---|
| DE 3710998A | April 1, 1987 | 1987DE-3710998 | N/A |

INT-CL (IPC): A61M 1/02

ABSTRACTED-PUB-NO: DE 3710998A
BASIC-ABSTRACT:

The appts. is used for treating a patient by the ozone therapy method. Blood is removed from the patient by inserting a cannula into the cubital vein and connecting the cannula by a flexible tube to a bottle. An anticoagulant is mixed with the blood in a defined proportion and a defined quantity of an ozone-oxygen mixture is added to the blood before the blood is returned to the patient.

The method of adding the anticoagulant involves a capsule (11) which contains a defined quantity of the anticoagulant. The outlet (12) from the capsule is pressed through the wall of a flexible hose (2) near to its junction with the cannula (1). The anti-coagulant is pressed out of the capsule (11) by a device (13) actuated by a thumb screw (15).

USE - Adding an anticoagulant to blood during therapy in which blood is removed from the body via a cannula.

CHOSEN-DRAWING: Dwg.2/2

TITLE-TERMS: INJECTION ANTICOAGULANT BLOOD CAPSULE ATTACH FLEXIBLE HOSE CONNECT CANNULA WITHDRAW BLOOD PATIENT

DERWENT-CLASS: P34

SECONDARY-ACC-NO:
Non-CPI Secondary Accession Numbers: N1988-228036

WEST

Generate Collection

L2: Entry 13 of 15 File: DWPI Dec 20, 1997

DERWENT-ACC-NO: 1998-375521
DERWENT-WEEK: 199832


TITLE: A method of treating neuro-dermatitis - by rectal introduction of an oxygen-ozone mixture and intramuscular injection of auto-blood saturated with oxygen-ozone mixture

INVENTOR: GLAVINSKAYA, T A; IVANOVA, O A

PATENT-ASSIGNEE:

| ASSIGNEE | CODE |
|---|---|
| NIZHEGOROD MED INST | NIZHR |
| NIZHEGOROD SKIN VENERAL RES INST | NIZHR |

PRIORITY-DATA: 1994RU-0026137 (July 14, 1994)

PATENT-FAMILY:

| PUB-NO | PUB-DATE | LANGUAGE | PAGES | MAIN-IPC |
|---|---|---|---|---|
| RU 2099061 C1 | December 20, 1997 | N/A | 004 | A61K033/00 |

APPLICATION-DATA:

| PUB-NO | APPL-DATE | APPL-NO | DESCRIPTOR |
|---|---|---|---|
| RU 2099061C1 | July 14, 1994 | 1994RU-0026137 | N/A |

INT-CL (IPC): A61K 33/00; A61M 1/14; A61M 1/32

ABSTRACTED-PUB-NO: RU 2099061C

BASIC-ABSTRACT:

A method of treating neuro-dermatitis by rectal introduction of an oxygen-ozone mixture (OOM)is new. The mixture contains 50 mu g ozone/litre of mixture. The mixture is introduced once daily in 400 cm3 volume over 18 days, with a daily increase of the volume introduced to 100 cm3 per day. The patient is also subjected to a daily i.m. injection of auto-blood, saturated with 15 cm3 of OOM, ozone concentration 50 mu g ozone/litre of mixture, twice per week, up to 10 injections.

ADVANTAGES - The method is more effective than previous methods and reduces complications.

CHOSEN-DRAWING: Dwg.0/0

TITLE-TERMS: METHOD TREAT NEURO DERMATITIS RECTUM INTRODUCING OXYGEN OZONE MIXTURE INTRAMUSCULAR INJECTION AUTO BLOOD SATURATE OXYGEN OZONE MIXTURE

DERWENT-CLASS: B06 P34

CPI-CODES: B04-B04D5; B05-C08; B14-N17C;

CHEMICAL-CODES:

Chemical Indexing M1 *01*
Fragmentation Code
M423 M431 M782 M903 P943 V600 V615

Chemical Indexing M2 *02*
Fragmentation Code
C108 C550 C810 M411 M431 M782 M903 M904 M910 P943
Specfic Compounds
01779M
Registry Numbers
1779U

Chemical Indexing M2 *03*
Fragmentation Code
C408 C550 C810 M411 M431 M782 M903 M904 M910 P943
Specfic Compounds
01887M
Registry Numbers
1887U

UNLINKED-DERWENT-REGISTRY-NUMBERS: 1779U; 1887U

SECONDARY-ACC-NO:
CPI Secondary Accession Numbers: C1998-113835
Non-CPI Secondary Accession Numbers: N1998-293627

WEST

Generate Collection

L2: Entry 10 of 15 File: DWPI Sep 20, 1999

DERWENT-ACC-NO: 2000-462870
DERWENT-WEEK: 200040


TITLE: Method of treatment of patients with malignant neoplasms in experiment

INVENTOR: KONTORSHCHIKOVA, K N; SHCHERBATYUK, T G

PATENT-ASSIGNEE:

| ASSIGNEE | CODE |
|---|---|
| NIZHEGOROD MED ACAD | NIZHR |
| SHCHERBATYUK T G | SHCHI |

PRIORITY-DATA: 1996RU-0124167 (December 24, 1996)

PATENT-FAMILY:

| PUB-NO | PUB-DATE | LANGUAGE | PAGES | MAIN-IPC |
|---|---|---|---|---|
| RU 2137481 C1 | September 20, 1999 | N/A | 000 | A61K033/00 |

APPLICATION-DATA:

| PUB-NO | APPL-DATE | APPL-NO | DESCRIPTOR |
|---|---|---|---|
| RU 2137481C1 | December 24, 1996 | 1996RU-0124167 | N/A |

INT-CL (IPC): A61K 33/00; A61K 33/14

ABSTRACTED-PUB-NO: RU 2137481C
BASIC-ABSTRACT:

NOVELTY - Invention proposes to use a physiological solution obtained by bubbling with ozone-oxygen mixture at the rate of gas flow 0.5-1 l/min for 15-20 min at ozone concentration in gaseous mixture 800-5 000 mcg/l. Solution is administrated into tumor directly by perimeter of its localization at volume 0.5-1.5 ml. Invention can be used for validity of the following study and using the ozonotherapy for treatment of patients with malignant neoplasms.

USE - Medicine, experimental oncology.

ADVANTAGE - Broadened arsenal of treatment methods. 5 tbl, 3 ex

CHOSEN-DRAWING: Dwg.0/0

TITLE-TERMS: METHOD TREAT PATIENT MALIGNANT NEOPLASMS EXPERIMENT

DERWENT-CLASS: B06

CPI-CODES: B05-C08; B14-H01B;

SECONDARY-ACC-NO:
CPI Secondary Accession Numbers: C2000-139394

WEST

Generate Collection

L2: Entry 9 of 15 File: EPAB Jul 28, 1992

PUB-NO: US005133975A
DOCUMENT-IDENTIFIER: US 5133975 A
TITLE: Method for in vivo inactivation of blood borne HIV virus using a mixture of ozone and oxygen

PUBN-DATE: July 28, 1992

INVENTOR-INFORMATION:

| NAME | COUNTRY |
|---|---|
| HARLEY, RICHARD J | US |
| BIMBI, PETER | US |
| GREENE, DON | US |
| WAINWRIGHT, BASIL | US |

ASSIGNEE-INFORMATION:

| NAME | COUNTRY |
|---|---|
| RJH AND COMPANY INC | US |

APPL-NO: US39435689
APPL-DATE: August 15, 1989

PRIORITY-DATA:

INT-CL (IPC): A61K 33/40
EUR-CL (EPC): A61K033/40

ABSTRACT:

The invention discloses a method for inactivating infectious agents in a patient's blood in vivo. The method involves adminstering to the patient a non-toxic, infectious agent inactivating amount of a mixture of oxygen and ozone. The mixture is preferably administered via rectal insufflation or via authohemotherapy.

WEST

Generate Collection

L2: Entry 3 of 15 File: USPT Feb 22, 2000

DOCUMENT-IDENTIFIER: US 6027688 A
TITLE: Apparatus and method for inactivation of human immunodeficiency virus

BSPR:
The invention is particularly adapted for the extra-corporeal treatment of human blood in a continuous process, wherein blood is withdrawn from a patient, circulated through the treatment apparatus of the invention and returned to the patient. Although the specific conditions of the treatment process may vary from patient to patient, depending upon the general health of the patient and the condition of the blood, satisfactory results are generally obtained when the blood is caused to flow through the gas-liquid contact apparatus at a flow rate of about 65 ml/min, typically achieved when the gas-liquid contact apparatus is inclined at an angle of about 27.degree. to the horizontal, and the concentration of ozone in the ozone-oxygen mixture is no more than about 27 .mu.g/ml and is at a surface pressure of about 2.2 psig.

WEST

Generate Collection

L2: Entry 14 of 15 File: DWPI Oct 12, 2000

DERWENT-ACC-NO: 1994-236472
DERWENT-WEEK: 200052


TITLE: Recovery of cell cultures with increased content of cytokine(s) - comprises gassing the patient's own blood with an ozone/oxygen mixt. and fractionating and conventional cell culture using lysates as stimulants

INVENTOR: KIEF, H

PATENT-ASSIGNEE:

| ASSIGNEE | CODE |
|---|---|
| KIEF H | KIEFI |
| KEEF H | KEEFI |

PRIORITY-DATA: 1992DE-4244437 (December 29, 1992)

PATENT-FAMILY:

| PUB-NO | PUB-DATE | LANGUAGE | PAGES | MAIN-IPC |
|---|---|---|---|---|
| DE 59310100 G | October 12, 2000 | N/A | 000 | A61K035/14 |
| EP 607593 A2 | July 27, 1994 | G | 003 | A61K035/14 |
| DE 4244437 A1 | July 28, 1994 | N/A | 003 | C12P021/00 |
| AU 9352790 A | July 14, 1994 | N/A | 000 | C12N005/00 |
| CA 2112314 A | June 30, 1994 | N/A | 000 | C12N005/02 |
| ZA 9309718 A | October 26, 1994 | N/A | 008 | C12P000/00 |
| JP 07087965 A | April 4, 1995 | N/A | 003 | C12N005/06 |
| EP 607593 A3 | December 14, 1994 | N/A | 000 | A61K035/14 |
| AU 672449 B | October 3, 1996 | N/A | 000 | C12N005/00 |
| EP 607593 B1 | September 6, 2000 | G | 000 | A61K035/14 |

DESIGNATED-STATES: AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

CITED-DOCUMENTS:No-SR.Pub; 2.Jnl.Ref ; EP 265548

APPLICATION-DATA:

| PUB-NO | APPL-DATE | APPL-NO | DESCRIPTOR |
|---|---|---|---|
| DE 59310100G | December 20, 1993 | 1993DE-0510100 | N/A |
| DE 59310100G | December 20, 1993 | 1993EP-0120536 | N/A |
| DE 59310100G | | EP 607593 | Based on |
| EP 607593A2 | December 20, 1993 | 1993EP-0120536 | N/A |
| DE 4244437A1 | December 29, 1992 | 1992DE-4244437 | N/A |
| AU 9352790A | December 24, 1993 | 1993AU-0052790 | N/A |
| CA 2112314A | December 23, 1993 | 1993CA-2112314 | N/A |
| ZA 9309718A | December 28, 1993 | 1993ZA-0009718 | N/A |
| JP 07087965A | December 28, 1993 | 1993JP-0352187 | N/A |
| EP 607593A3 | December 20, 1993 | 1993EP-0120536 | N/A |
| AU 672449B | December 24, 1993 | 1993AU-0052790 | N/A |
| AU 672449B | | AU 9352790 | Previous Publ. |
| EP 607593B1 | December 20, 1993 | 1993EP-0120536 | N/A |

INT-CL (IPC): A61K 35/14; A61K 37/02; A61K 37/66; A61K 38/00; A61K 38/21; C12N 5/00; C12N 5/02; C12N 5/06; C12N 5/08; C12P 0/00; C12P 21/00; C12P 21/00; C12R 1/91

ABSTRACTED-PUB-NO: EP 607593A
BASIC-ABSTRACT:

Recovering cell cultures with an increased content of the body's own cytokines comprises gassing blood cultures from the patient with an ozone, oxygen mixt. and fractionating comprising cultivating the cell cultures in known manner and adding lysates as stimulants, these lysates having been obtd. by ozonolysis and proteolysis of blood or blood fractions and/or urine.

The cell cultures are full blood, leucocytes, lymphocytes or mixed cultures.

USE/ADVANTAGE - The process can be used to obtain cytokines from the patient's own body, which (on account of their origin) can be given back to the same organism and are better tolerated in that they have been left in the body's own medium. The cytokines are obtd. more cheaply than previously and are better tolerated by the patient's body. Yields are higher than in previous processes.
ABSTRACTED-PUB-NO:

EP 607593B
EQUIVALENT-ABSTRACTS:

Recovering cell cultures with an increased content of the body's own cytokines comprises gassing blood cultures from the patient with an ozone, oxygen mixt. and fractionating comprising cultivating the cell cultures in known manner and adding lysates as stimulants, these lysates having been obtd. by ozonolysis and proteolysis of blood or blood fractions and/or urine.

The cell cultures are full blood, leucocytes, lymphocytes or mixed cultures.

USE/ADVANTAGE - The process can be used to obtain cytokines from the patient's own body, which (on account of their origin) can be given back to the same organism and are better tolerated in that they have been left in the body's own medium. The cytokines are obtd. more cheaply than previously and are better tolerated by the patient's body. Yields are higher than in previous processes.

CHOSEN-DRAWING: Dwg.0/0

TITLE-TERMS: RECOVER CELL CULTURE INCREASE CONTENT CYTOKINE COMPRISE GAS PATIENT BLOOD OZONE OXYGEN MIXTURE FRACTIONATE CONVENTION CELL CULTURE LYSATE

STIMULATING

DERWENT-CLASS: B04 D16

CPI-CODES: B04-J01; D05-H08; D05-H13;

CHEMICAL-CODES:

Chemical Indexing M1 *01*
Fragmentation Code
M423 M720 M903 N161 N511 N512 N513 Q233 V752 V753

SECONDARY-ACC-NO:
CPI Secondary Accession Numbers: C1994-107539